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the atria correlates with procollagen I carboxyl
terminal peptide and TGF-β1 levels in serum of
patients with atrial fibrillation
Fei Zhao, ShiJiang Zhang, YiJiang Chen, WeiDong Gu, BuQing Ni, YongFeng Shao*, YanHu Wu and JianWei QinAbstract
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice. Unfortunately, the
precise mechanisms and sensitive serum biomarkers of atrial remodeling in AF remain unclear. The aim of this
study was to determine whether the expression of the transcription factors NF-AT3 and NF-AT4 correlate with atrial
structural remodeling of atrial fibrillation and serum markers for collagen I and III synthesis.
Methods: Right and left atrial specimens were obtained from 90 patients undergoing valve replacement surgery.
The patients were divided into sinus rhythm (n = 30), paroxysmal atrial fibrillation (n = 30), and persistent atrial
fibrillation (n = 30) groups. NF-AT3, NF-AT4, and collagen I and III mRNA and protein expression in atria were
measured. We also tested the levels of the carboxyl-terminal peptide from pro-collagen I, the N-terminal type I
procollagen propeptides, the N-terminal type III procollagen propeptides, and TGF-β1 in serum using an enzyme
immunosorbent assay.
Results: NF-AT3 and NF-AT4 mRNA and protein expression were increased in the AF groups, especially in the left
atrium. NF-AT3 and NF-AT4 expression in the right atrium was increased in the persistent atrial fibrillation group
compared the sinus rhythm group with similar valvular disease. In patients with AF, the expression levels of nuclear
NF-AT3 and NF-AT4 correlated with those of collagens I and III in the atria and with PICP and TGF-β1 in blood.
Conclusions: These data support the hypothesis that nuclear NF-AT3 and NF-AT4 participates in atrial structural
remodeling, and that PICP and TGF-β1 levels may be sensitive serum biomarkers to estimate atrial structural
remodeling with atrial fibrillation.
Keywords: Atrial fibrillation, Atrial fibrosis, Transcription factor, NF-AT3, NF-AT4, Carboxyl terminal peptide
from pro-collagen I, N-terminal type I procollagen propeptides, N-terminal type III procollagen propeptidesBackground
Atrial fibrillation (AF) is the most common cardiac
arrhythmia in clinical practice [1,2]. Valvular heart dis-
ease (VHD), which comprises pathological changes in the
mitral or aortic valves, causes AF. Valvular surgery is an
option to prevent heart failure in serious VHD patients
[3,4]. AF is self-perpetuating because tachyarrhythmia
causes electrophysiological and structural changes that* Correspondence: shaoyongfeng6708@aliyun.com
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unless otherwise stated.exacerbate or maintain AF [5]. This structural remodel-
ing can contribute to both the development and mainten-
ance of AF [6,7]. Several factors associated with atrial
structural remodeling have been identified [8], of which
atrial fibrosis and myocyte hypertrophy are considered
key [9].
Atrial fibrosis is a hallmark of arrhythmogenic struc-
tural remodeling [10,11]. Cardiac fibrosis is defined as a
detrimental process causing imbalanced extracellular
matrix deposition and heart degradation. Cardiac fibrosis
causes excessive fibroblast proliferation and accumu-
lation of extracellular matrix proteins in the cardiactd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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matrix between cardiomyocytes may cause conduction
delays and create alternate conduction pathways. These
changes also result in ectopic foci and anisotropic con-
duction, creating nonuniform wave fronts that facilitate
abnormal reentrant arrhythmias [13]. Unfortunately, the
precise mechanisms of atrial remodeling in AF remain
unclear.
Atrial structural remodeling consists primarily of co-
llagens I and III, and the process of fibrosis is regulated
by a cascade of fibro-proliferative signals, including
TGF-β1 and angiotensin II [2,14]. Calcineurin is a Ca2+-
calmodulin-activated serine/threonine phosphatase that
is ubiquitously expressed and plays an important role in
transducing Ca2+-dependent signals. Calcineurin is a
heterodimer comprising a calmodulin binding catalytic
subunit A and a Ca2+ binding regulatory subunit B. Cal-
cineurin is required for activation of transcription and
induction of cell hypertrophy in a number of cell types
including cardiac myocytes [15,16]. Activation of calcine-
urin was reported to be increased in atrial tissues of pa-
tients with AF [17]. Calcineurin dephosphorylates NF-
AT3 and NF-AT4, which induces their translocation
from the cytosol to the nucleus where they activate the
transcription of their target genes [17-19]. Transgenic
mice that constitutively express calcineurin in cardio-
myocytes can develop cardiac hypertrophy and a con-
comitant accumulation of collagen deposits surrounding
the degenerating cardiomyocytes [19-21]. Calcineurin
inhibitors such as cyclosporin A and FK506 can inhibit
TGF-β1 expression to block increased extracellular mat-
rix protein accumulation [22]. Furthermore, a constitu-
tively active NF-AT 3 and NF-AT4 expressed in the
hearts of transgenic mice produced cardiac wall fibrosis
and cardiac myocyte enlargement, demonstrating the im-
portance of a calcium-calcineurin-NF-AT3 pathway in
cardiac fibrosis and hypertrophy [19].
The transcription factors NF-AT3 and NF-AT4 are the
downstream effectors of calcineurin, and play an import-
ant role in the calcineurin-dependent pathway during
cardiac hypertrophy [19,23]. Recent studies also directly
and indirectly implicate the calcineurin-dependent path-
way in the development of cardiac fibrosis [19,20,24,25].
In addition, the N-terminal propeptides of collagen types I
or III (PINP and PIIINP, respectively) and the C-terminal
propeptides (PICP) in the blood have been reported to be
useful markers of collagen type I or III synthesis [26].
In the present study, we examined the correlation be-
tween nuclear NF-AT3 and NF-AT4 expression and dis-
tribution with collagens I and III expression levels in
diseased atrial tissues of patients with AF. We also ex-
amined the correlations between serum levels of TGF-
β1, PINP, PIIINP, and PICP with NF-AT3 and NF-AT4
expression in the nucleus and with collagen I and IIIexpression in atrial tissues. In patients with AF, we found
that the expression levels of nuclear NF-AT3 and NF-
AT4 correlated with those of collagens I and III in the
atria and with PICP and TGF-β1 in blood.
Methods
Patients
We recruited 90 VHD patients, comprising pathological
changes in the mitral or aortic valves, or both, admitted
to the First Affiliated Hospital of Nanjing Medical Uni-
versity for valve replacement surgery from January 2012
to January 2013. The patients were divided into three
groups: sinus rhythm (SR; n = 30), persistent AF (PeAF;
AF lasting >6 month, n = 30), and paroxysmal AF (PaAF;
recurrent AF that terminated spontaneously in <7 days,
n = 30). The control group (n = 10) comprised patients
with congenital heart disease and SR who underwent
heart surgery. We excluded four categories of patients
from this study: (i) patients with renal dysfunction
(serum creatinine >136 μmol/L) or Type II diabetes, (ii)
patients whose coronary angiography and echocardio-
graphic evaluation indicated coronary artery bypass graft-
ing or associated procedures, (iii) patients >70 years, or
those with a history of some diseases (e.g., hyperthyroid-
ism) that influence AF risk, and (iv) patients with fibrosis
disease that could affect serum fibrosis biomarkers. Pre-
operative medications, except warfarin and angiotensin-
converting enzyme inhibitors, were continued until the
morning of the surgery. Prior to surgery, an investigator
assessed the preoperative clinical characteristics of the
patients. Before discharge, another investigator recorded
detailed operative data. The Ethics Committee of Nanjing
Medical University approved the study protocol, and all
patients provided written consent prior to enrollment.
The investigation adhered to the principles outlined in
the Declaration of Helsinki.
Human cardiac tissue collection and storage
The same cardiac anesthesiologist, perfusionist, and surgi-
cal team performed all surgeries. All patients underwent
cardiopulmonary bypass with moderate hypothermia (33–
34°C). Antegrade crystalloid cardioplegia was used to ar-
rest the heart, and local hypothermia was maintained
with ice slush. A cardioplegic solution was readminis-
tered every 20–30 min. Approximately 250 mg of right
atrial appendage (RAA) tissue was collected from the
cannulation site, and approximately 250 mg of left atrial
appendage (LAA) tissue was collected in the PeAF and
PaAF group before initiating extracorporeal circulation.
In our department, LAA ligation and resection is a rou-
tine surgical maneuver in rheumatic valvular disease pa-
tients with AF. To minimize damage, we only collected
LAA samples from the AF group; this surgical maneuver
was not necessary in the SR group. The sample site was
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portion of RAA and LAA tissue was fixed in 4% parafor-
maldehyde for histology and immunohistochemistry. The
remaining tissue was snap-frozen in liquid nitrogen for
other analyses.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from the atrial tissue samples and
treated with RNase-free water according to the TRIzol®
(Invitrogen, Carlsbad, CA, USA) method. Single-stranded
cDNA was synthesized from the total RNA as follows.
In brief, 2 μg RNA was preincubated with 1.5 μL oligo
(dT)18 primer (10 μmol/L; Genscript Technology Co.,
Nanjing, China), and diethylpyrocarbonate (DEPC)-
treated water (0.1% DEPC; Keygen, China) in a total vol-
ume of 10 μL. This solution was incubated at 70°C for
10 min and then rapidly chilled on ice. The reaction was
initiated by incubation at 42°C for 1 h in a Multigene™
Gradient TC9600-G-230 V thermal cycler (Labnet Inter-
national Inc., Edison, NJ, USA) and was deactivated at
70°C for 15 min, followed by immersion in ice. The re-
sultant cDNA was used as a template for subsequent
PCR. Thirty cycles of PCR amplification were performed,
with initial incubation at 94°C for 5 min and final exten-
sion at 72°C for 5 min. Each cycle comprised denatur-
ation at 94°C for 30 s, annealing at 55°C for 30 s, and
extension at 72°C for 30 s. The collagen I, collagen III,
NF-AT3, and NF-AT4 genes were amplified using the fol-
lowing specific primers: collagenI (sense: 5′- TTCCTGC
GCCTGATGTCC −3′, antisense: 5′- GGTTCAGTTTGG
GTTGCTTGT −3′); collagenIII (sense: 5′- TCAACACC
GATGAGATTATGAC −3′, antisense: 5′- CAAAGGATT
GGCACTTATGC −3′); NF-AT3 (sense: 5′- GGGACAAC
AGAACCAGAGTAAC −3′, antisense: 5′- AAACAGAAT
AGTCCACCTTGAGA −3′); NF-AT4 (sense: 5′- TTGGA
ACACCAGCCATCAGG −3′, antisense: 5′- GCTGCTC
CTGTTCTTTTGCC −3′). The quantities of cDNA that
produced an equal amount of GAPDH PCR product
were used for PCR using the primers for collagenI, col-
lagenIII, NF-AT3, and NF-AT4. PCR product levels were
semiquantitatively determined using a digital camera and
an image analysis system (Gel Doc™ XR; Bio-Rad,
Hercules, CA, USA), followed by normalization against
GAPDH expression.
Western blotting
In preparation of whole tissue extracts, atrial tissue sam-
ples were homogenized on ice in RIPA lysis buffer
(Thermo Fisher Scientific Inc, Rockford, IL USA). Ly-
sates were incubated on ice for 10 min at 4°C and subse-
quently centrifuged at 9300 × g for 10 min. Supernatants
were saved and stored at −70°C. Nuclear extracts were
prepared as follows [17]. Approximately 250 mg of atrial
tissue was washed with cold PBS, homogenized, andresuspended in 1 ml of hypotonic buffer. Homogenates
were incubated for 10 min on ice and centrifuged
(10 min, 800 × g at 4°C). Pellets were resuspended in
0.15 ml of hypertonic buffer and incubated on ice for
20 min. Samples were centrifuged (10 min, 13 000 × g at
4°C), and supernatants (nuclear protein extract) were
stored in aliquots at −80°C. Protein concentrations were
determined using the Lowry method, and absorbance was
measured spectrophotometrically (UV 2540; Shimadzu,
Kyoto, Japan). Denatured samples were subjected to
western blotting as follows. Samples containing 25 μg of
protein were electrophoretically separated on a 10% SDS-
polyacrylamide gel for 1.5 h at 120 V, and the proteins
were transferred to nitrocellulose membranes (Pall Cor-
poration, Ann Arbor, MI, USA). After blocking in 5%
fat-free milk, the membranes were incubated overnight
at 4°C with primary antibodies (dilution) against collagen
I (1:200, Biosynthesis Biotechnology Company, Inc.,
Beijing, China), collagen III (1:200, Bioss), NF-AT3
[1:1000; Cell Signaling Technology Inc., USA), and NF-
AT4 (1:1000; Cell Signaling Technology). Anti-GAPDH
(1:1000; Cell Signaling Technology Inc.) and anti-lamin B
(1:1000; Cell Signaling Technology Inc.) polyclonal anti-
bodies were used as controls to normalize the data. The
membranes were then incubated for 2 h at 37°C with sec-
ondary antibodies (goat anti-rabbit IgG diluted in PBS
containing 5% fat-free milk and 0.1% Tween-20). The
stained membranes were visualized using enhanced
chemiluminescence with the ECL Plus reagent (GE
Healthcare, Chalfont St. Giles, Buckinghamshire, UK).
Western blotting was repeated at least thrice per sample
with similar results.
Blood sampling and enzyme-linked-immunosorbent sero-
logic assay (ELISA)
Venous blood samples were obtained in EDTA from
every patient before surgery. Serum was separated by
centrifugation (1800 × g, 5 min, room temperature), and
stored at −80°C until analysis. Serum PIIINP, PINP, TGF-
β1, and PICP levels were determined by sensitive ELISA
kits (Senxiong Biotechnology Industry Inc., Shanghai,
China), according to the manufacturer’s instructions. As-
says were performed in duplicate in a single run and nor-
malized to a standard curve.
Histology and immunohistochemistry
RAA and LAA samples were fixed with 4% paraformal-
dehyde in phosphate-buffered saline (pH 7.4) for 24 h.
After alcohol dehydration, the tissues were embedded in
paraffin and sectioned. The 2-μm-thick serial sections
were then stained with Van Gieson’s solution for micro-
scopic examination. For NF-AT3 and NF-AT4 (Biosis)
detection, immunoreactivity was performed on 4-μm-
thick sections of the paraffin-embedded tissues. Brown
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positive. Hypertrophic heart ventricle tissues were se-
lected as a positive control, and negative controls were
sections incubated with antibodies pre-absorbed with
the NF-AT3 and NF-AT4 peptide (Abcam). The entire
sections were scanned at low magnification (×100) ini-
tially to select regions, and then high magnification
(×400) was used for focused investigation.Table 1 Analysis of clinical data
SR + CHD
Patient number 10
Sex, M/F (n) 4/6
Age (years) 16.20 ± 3.31
Preoperative data
Heart rate (beats/min) 102.4 ± 4.51
NYHA class I/II/III/IV 2/7/1/0
Echocardiographic parameters
LVDd 34 ± 2.30
LVDs 24 ± 3.11
EF (%) 64 ± 4.12
LAD (mm) 23 ± 6.73
RAD (mm) 27 ± 8.71




















CPB duration 78 ± 11.44
Aortic clamp time 45.32 ± 33.32
Data are presented as n or mean ± standard deviation.
AVD, aortic valve disease; CHD, Congenital heart disease; DVD, Double valvular dise
atrial fibrillation; PeAF, Persistent atrial fibrillation; SR, Sinus rhythm; VHD, Valvular h
aPaAF + VHD vs. SR + VHD; P < 0.01. bPeAF + VHD vs. SR + VHD; P < 0.01. cLAD vs. RAStatistical analyses
Values are expressed as the mean ± standard deviation.
Differences among three or more groups were analyzed
using the Kruskal–Wallis test. Differences between any
two groups were analyzed using the Mann–Whitney U
test. Chi-square and Fisher’s exact tests were used to de-
termine the differences between the groups. Univariate
regression tests were used to assess the associationsSR + VHD PaAF + VHD PeAF + VHD
30 30 30
16/14 13/17 12/18
54.75 ± 3.68 55.61 ± 6.83 53.58 ± 4.63
79 ± 6.00 81 ± 7.00 83 ± 9.20
0/12/10/8 0/7/13/10 0/5/12/13
53.55 ± 8.70 55.66 ± 14.13 54.97 ± 12.36
36.38 ± 1.26 39 ± 10.22 34.13 ± 11.03
55.01 ± 4.80 53.08 ± 5.32 52.21 ± 5.21
47.25 ± 5.19c 55.43 ± 6.80a,c 59.23 ± 5.92b,c
38.40 ± 5.20 38.10 ± 4.64 38.20 ± 5.00
















130 ± 12.42 141 ± 23.44 145 ± 13.23
79 ± 34.43 82 ± 35.26 90 ± 42.13
ase (mitral and aortic valves); MVD, Mitral valvular disease; PaAF, Paroxysmal
eart disease.
D; P < 0.01.
Table 2 PIIINP, PINP, PICP, and TGF-β1 blood levels
PeAF + VHD (n = 30) PaAF + VHD (n = 30) SR + VHD (n = 30) SR + CHD (n = 10)
PIIINP (ng/ml) 88.03 ± 46.08b,c 72.96 ± 43.30d 52.50 ± 29.32e 14.09 ± 2.732
PINP (ng/ml) 45.41 ± 42.17c 34.82 ± 28.60 18.95 ± 17.34 6.940 ± 3.007
TGF-β1 (pg/ml) 49.01 ± 28.67a,b,c 27.96 ± 13.16d 24.09 ± 14.10 11.43 ± 2.695
PICP (ng/ml) 43.42 ± 3.699a,b,c 36.06 ± 7.710d 29.75 ± 9.241e 12.52 ± 3.033
Data are presented as n or mean ± standard deviation.
CHD, Congenital heart disease; PaAF, Paroxysmal atrial fibrillation; PeAF, Persistent atrial fibrillation; PICP, carboxyl-terminal peptide from pro-collagen I; PINP,
N-terminal type I procollagen propeptides; PIIINP, N-terminal type III procollagen propeptides; SR, Sinus rhythm; VHD, Valvular heart disease.
aPeAF + VHD vs. PaAF + VHD; P < 0.05. bPeAF + VHD vs. SR + VHD; P < 0.05. cPeAF + VHD vs. SR + CHD; P < 0.05. dPaAF + VHD vs. SR + CHD; P < 0.05. eSR + VHD
vs. SR + CHD; P < 0.05.
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nucleus, collagens I and III in atrial tissue, and PINP,
PIIINP, PICP, and TGF-β1 in the blood. Differences
yielding p <0.05 were considered significant. Data were
analyzed using GraphPad Prism version 5.01 and STATA
version 10.0.530.0.
Results
Clinical characteristics and hemodynamic data
Preoperative hemodynamic and echocardiographic data
are shown in Table 1. Statistical analysis showed thatFigure 1 Immunohistochemistry for NF-AT3 (stained brown) in sectio
(right atrium), PaAF (left atrium), PeAF (right atrium), and PeAF (left a
right and left atrial tissues were identified in the PeAF groups compared w
selected as a positive control, and negative controls were sections incubate
Magnification (×400). CHD, Congenital heart disease; SR, Sinus rhythm; PaA
Nuclear factor of activated T cells 3; NF-AT4, Nuclear factor of activated T cleft atrial diameter, measured by echocardiography, was
significantly larger in the PeAF group than in the SR
group. Furthermore, the left atrial diameter was signifi-
cantly larger than the right atrial diameter in all groups,
except for the control group. Right atrial diameters, left
ventricular end systolic dimensions (LVDs), and left
ventricular end diastolic dimensions were not signifi-
cantly different among the three VHD groups. The con-
stituent ratios of patients with different heart functions
were not significantly different among the three VHD
groups.ns obtained from the CHD (right atrium), SR (right atrium), PaAF
trium) groups. Nuclei are in blue. Elevated levels of NF-AT3 in the
ith the SR and CHD groups. Hypertrophic heart ventricle tissues were
d with antibodies pre-absorbed with the NF-AT3 and NF-AT4 peptide.
F, Paroxysmal atrial fibrillation; PeAF, Persistent atrial fibrillation; NF-AT3,
ells 4.
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increased in the AF groups
The levels of PICP and TGF-β1 were significantly in-
creased in the PeAF group compared with the PaAF and
SR groups. However, there were no differences in PIIINP
levels between the PeAF and PaAF groups, while PIIINP
levels in the PeAF group were only significantly higher
than those in the SR group. Levels of PINP in the PeAF
group were significantly greater than those in the control
group, while there were no differences in PINP levels be-
tween the PeAF and the other groups (Table 2).
Expression of collagen I, collagen III, NF-AT3, and
NF-AT4 mRNA and protein were increased in the
AF groups
Immunohistochemistry showed that total NF-AT3
(Figure 1) and NF-AT4 (Figure 2) expression were upreg-
ulated in the AF groups compared with the SR and con-
trol groups. We also demonstrated that collagen I,
collagen III, total NF-AT3, and NF-AT4 expression were
upregulated in the AF groups using RT-PCR and western
blotting (Figure 3A,B; Figure 4A,B). We also demon-
strated that nuclear NF-AT3 and NFAT4 expression wasFigure 2 Immunohistochemistry for NF-AT4 (stained brown) in sectio
(right atrium), PaAF (left atrium), PeAF (right atrium), and PeAF (left a
right and left atrial tissues were identified in the PeAF groups compared w
selected as a positive control, and negative controls were sections incubate
Magnification (×400). CHD, Congenital heart disease; NF-AT3, Nuclear facto
PaAF, Paroxysmal atrial fibrillation; PeAF, Persistent atrial fibrillation; SR, Sinuupregulated in the AF group compared with the SR group
(Figure 5A,B).
Analysis of the expression of NF-AT3 and NF-AT4 and
collagens I and III in the right and left atria of patients
with AF
In the left atrium of patients with AF, collagen I mRNA
expression was not correlated with NF-AT3 and NF-
AT4 mRNA expression. Collagen I protein expression
was positively correlated with nuclear NF-AT3 expres-
sion (p <0.01), but not with nuclear NF-AT4 expression.
Levels of collagen III mRNA expression were positively
correlated with NF-AT4 mRNA expression (p < 0.01),
but not with NF-AT3 expression. Collagen III protein
expression was positively correlated with nuclear NF-
AT3 (p <0.01) and nuclear NF-AT4 expression (p <0.01).
In the right atrium of patients with AF, collagen I
mRNA expression was correlated with NF-AT3 (p <0.01)
and NF-AT4 mRNA expression (p <0.01). Collagen I
expression was correlated with nuclear NF-AT3 expres-
sion (p <0.01), but not with nuclear NF-AT4 expression.
Collagen III mRNA expression was correlated with NF-
AT3 (p <0.01) and NF-AT4 mRNA expression (p <0.01).ns obtained from the CHD (right atrium), SR (right atrium), PaAF
trium) groups. Nuclei are in blue. Elevated levels of NF-AT3 in the
ith the SR and CHD groups. Hypertrophic heart ventricle tissues were
d with antibodies pre-absorbed with the NF-AT3 and NF-AT4 peptide.
r of activated T cells 3; NF-AT4, Nuclear factor of activated T cells 4;
s rhythm.
Figure 3 Collagen I,collagen III,NF-AT3 and NF-AT4 mRNA expression in the different groups (A) Collagen I and collagen III mRNA
expression in the different groups. *P < 0.05. (B) NF-AT3 and NF-AT4 mRNA expression in the different groups. *P < 0.05. GAPDH indicates a
representative blot. NF-AT3, Nuclear factor of activated T cells 3; NF-AT4, Nuclear factor of activated T cells 4.
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Figure 4 Collagen I,collagen III,NF-AT3 and NF-AT4 protein expression in the different groups (A) Collagen I and collagen III protein
expression in the different groups. P < 0.05. (B) NF-AT3 and NF-AT4 protein expression in the different groups. *P < 0.05. GAPDH indicates a
representative blot. NF-AT3, Nuclear factor of activated T cells 3; NF-AT4, Nuclear factor of activated T cells 4.
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AT3 expression (p <0.01) and nuclear NF-AT4 (p <0.01)
(Table 3).
Correlation between collagen I and collagen III levels in
the right and left atria with PIIINP, PINP, TGF-β1, and PICP
levels in the blood of patients with AF
In the left atrium of patients with AF, collagen I levels
were correlated with PICP (p = 0.001) and PINP levels
(p = 0.003), but not with TGF-β1 levels. The level of
collagen III was correlated with PIIINP (p <0.001) and
TGF-β1 levels (p = 0.0042). Collagen I levels werecorrelated with PICP (p = 0.019) and TGF-β1 levels
(p <0.05), while there was no correlation of collagen III
levels with PIIINP and TGF-β1 levels in the right atrium
of patients with AF (Table 4).
Correlation between nuclear NF-AT 3 and NF-AT 4 levels
in the right and left atria and PIIINP, PINP, TGF-β1, and
PICP levels in the blood of patients with AF
In the left atrium of patients with AF, nuclear NF-AT3
levels were correlated with PICP (p <0.01) and TGF-β1
levels (p <0.01), while nuclear NF-AT4 levels correlated
with PICP (p <0.01) and TGF-β1 levels (p <0.05). In the
Figure 5 Nuclear NF-AT3 and Nuclear NF-AT4 protein expression in the different groups (A) Nuclear NF-AT3 protein expression in the
different groups. *P < 0.05. (B) Nuclear NF-AT4 protein expression in the different groups. *P < 0.05. Laminb1 indicates a representative blot.
NF-AT3, Nuclear factor of activated T cells 3; NF-AT4, Nuclear factor of activated T cells 4.
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were correlated with PICP (p <0.01) and TGF-β1 levels
(p <0.01), while nuclear NF-AT4 levels correlated with
PINP (p <0.01) and PICP levels (p <0.05 (Table 5).
Analysis of NF-AT3 and NF-AT4 protein expression in the
right atria of patients with different valvular disease
In the right atrium, the total NF-AT3 expression in pa-
tients in the AF group was higher than that in patientsTable 3 Correlation between expression of collagens and
nuclear NF-AT3 and NF-AT4 in the left and right atria of
patients with atrial fibrillation mRNA
NF-AT3 NF-AT4
Collagen I Left atrium NF-AT3 mRNA NF-AT4 mRNA
mRNA Not significant Not significant
Right atrium NF-AT3 mRNA NF-AT4 mRNA
r = 0.351, P < 0.01 r = 0.412, P < 0.01
Collagen III Left atrium NF-AT3 mRNA NF-AT4 mRNA
mRNA Not significant r = 0.354, P < 0.01
Right atrium NF-AT3 mRNA NF-AT4 mRNA
r = 0.526, P < 0.01 r = 0.420, P < 0.01
NF-AT3 NF-AT4
Collagen I Left atrium NF-AT3 protein NF-AT4 protein
protein r = 0.447, P < 0.01 No significant
Right atrium NF-AT3 protein NF-AT4 protein
r = 0.469, P < 0.01 Not significant
Collagen III Left atrium NF-AT3 protein NF-AT4 protein
protein r = 0.774, P < 0.01 r = 0.421, P < 0.01
Right atrium NF-AT3 protein NF-AT4 protein
r = 0.740, P < 0.01 r = 0.404, P < 0.01
NF-AT3, Nuclear factor of activated T cells 3; NF-AT4, Nuclear factor of
activated T cells 4.in the SR group with mitral valve disease (MVD). NF-
AT3 expression in patients in the PeAF group was
higher than that in patients in the PaAF and SR groups
with double-valve disease (DVD) (p <0.05). The total
NF-AT3 expression in patients in the AF group was
higher than that in those in the SR group with aortic
valve disease (AVD) (p <0.05). NF-AT3 expression in pa-
tients with MVD and DVD was higher than those with
AVD in the PeAF group, while NF-AT3 expression in
patients with MVD was higher than in those with DVD
or AVD in the PaAF group (p <0.05). NF-AT3 expres-
sion in patients with MVD was higher than those with
DVD or AVD in the SR group (p <0.05). NF-AT4 ex-
pression in patients in the PeAF group was higher than
those in the PaAF and SR groups with MVD, while NF-
AT4 expression in the PeAF group was higher than
those in the PaAF and SR groups with DVD (p <0.05).
NF-AT4 expression in patients in the PeAF group was
higher than those in the SR group with AVD (p <0.05).
NF-AT4 expression in patients with MVD and DVD wasTable 4 Correlation between serum fibrosis biomarkers
and collagen levels in the right and left atria of patients
with atrial fibrillation
Fibrosis biomarker
Collagen I Left atrium PICP PINP
r = 0.386, P = 0.001 r = 0.423, P = 0.003
Right atrium PICP TGF-β1
r = 0.336, P = 0.019 r = 0.258, P < 0.05
Collagen III Left atrium TGF-β1 PIIINP
r = 0.469, P < 0.001 r = 0.291, P = 0.042
Right atrium Not significant Not significant
PICP, carboxyl-terminal peptide from pro-collagen I; PINP, N-terminal type I
procollagen propeptides; PIIINP, N-terminal type III procollagen propeptides.
Table 5 Correlation between markers of serum fibrosis
and levels of nuclear NF-AT3 and NF-AT4 in the right and
left atria of patients with atrial fibrillation
Fibrosis biomarker
Nuclear Left atrium PICP TGF-β1
NF-AT3 r = 0.538, P < 0.01 r = 0.444, P < 0.01
Right atrium PICP TGF-β1
r = 0.538, P < 0.01 r = 0.387, P < 0.01
Nuclear Left atrium PICP TGF-β1
NF-AT4 r = 0.282, P < 0.01 r = 0.324, P < 0.05
Right atrium PICP PINP
r = 0.264, P < 0.05 r = 0.316, P < 0.01
NF-AT3, Nuclear factor of activated T cells 3; NF-AT4, Nuclear factor of
activated T cells 4; PICP, carboxyl-terminal peptide from pro-collagen I; PINP,
N-terminal type I procollagen propeptides.
Table 6 Protein expression of total NF-AT3 and NF-AT4 in















DVD 0.880 ± 0.183c,d,h
(n = 13)
0.516 ± 0.053 (n = 9) 0.331 ± 0.050
(n = 10)































Data are presented as n or mean ± standard deviation.
AVD, aortic valve disease; MVD, Mitral valvular disease; DVD, Double valvular
disease (mitral and aortic valves); PaAF, Paroxysmal atrial fibrillation; PeAF,
Persistent atrial fibrillation; SR, Sinus rhythm.
aMVD + PeAF group vs. MVD+ SR group; P < 0.05. bMVD + PaAF group vs.
MVD + SR group; P < 0.05. cDVD + PeAF group vs. DVD + SR group; P < 0.05.
dDVD + PeAF group vs. DVD + PaAF group; P < 0.05. eAVD + PeAF group vs.
AVD + SR group; P < 0.05. fAVD + PaAF group vs. AVD + SR group P < 0.05.
gMVD + PeAF group vs. AVD + PeAF group; P < 0.05. hDVD + PeAF group vs.
AVD + PeAF group; P < 0.05. iMVD + PaAF group vs. AVD + PaAF group;
P < 0.05. jMVD + PaAF group vs. DVD + PaAF group P < 0.05. kMVD + SR
group vs. AVD + SR group; P < 0.05. lDVD + SR group vs. AVD + SR group;
P < 0.05. DVD: Double valve disease; MVD: Mitral valve disease; AVD: Aortic
valve disease.
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NF-AT4 expression in patients with MVD was higher
than those with AVD in the PaAF group (p <0.05). NF-
AT4 expression in patients with MVD and DVD was
higher than those with AVD in the SR group (p <0.05;
Table 6).
Discussion
Atrial structural remodeling underlies AF development
[8]. AF can cause structural remodeling that can exacer-
bate or maintain AF [5], while valvular disease also can
induce atrial remodeling. However, the precise mecha-
nisms of atrial remodeling in AF remain unclear. The
development of sensitive serum biomarkers reflecting
atrial remodeling may provide a simple method to deter-
mine the presence of atrial remodeling, allowing initi-
ation of timely therapeutic interventions. In the present
study, we determined that total NF-AT3 and NF-AT4
expression was increased in the PeAF group (particularly
in the left atrium) and the AF group.
As dilated atria caused by valvular disease can affect
atrial fibrosis and induce expression of related proteins,
comparisons of left atria between the PeAF and SR
groups may be confounded differences in left atrial sizes.
By contrast, right atrial diameters were not significantly
different between the three groups, and were thus con-
sidered suitable for studying the direct effects of AF on
atrial remodeling. In the right atria, we found that NF-
AT3 and NF-AT4 expression was increased in the PeAF
group compared with that in the SR group with similar
valvular disease. Moreover, NF-AT3 and NF-AT4 ex-
pression in patients with pure mitral valvular disease
was increased compared with that in patients with pure
aortic valvular disease in the PeAF, PaAF, and SR groups.
These data suggest that expression of NF-AT3 and NF-
AT4 are altered by atrial fibrillation and valvular disease
(particularly MVD). Thus, atrial fibrillation may be animportant factor affecting NF-AT3/4 expression and
atrial remodeling.
We also found a significant relationship between the
expression of collagen and nuclear NF-AT3 and NF-AT4
(Table 6). Collagens I and III are secreted as pro-collagen
precursors containing amino- and carboxyl-terminal pro-
peptides, which are released into the serum by proteases
after collagen deposition [27]. The N-terminal propep-
tides of collagen I or III (PINP and PIIINP, respectively)
and the C-terminal propeptides (PICP) are used as markers
of collagen type I or III synthesis [26]. We demonstrated
that serum PINP, PIIINP, and PICP were increased in the
PeAF group. Final analyses showed that PINP (PIN, r =
0.423 > PICP, r = 0.386) and TGF-β1 (TGF-β1, r = 0.469 >
PIIINP, r = 0.291) were sensitive fibrosis biomarkers for
the left atria of AF patients, while PICP (PICP, r = 0.336 >
TGF-β1, r = 0.258) was a sensitive fibrosis biomarker for
the right atria. To establish the extent of right and left
atrial fibrosis, PICP and TGF-β1 are likely the most sen-
sitive fibrosis biomarkers. We also found that serum
PICP and TGF-β1 levels were the optimal biomarkers for
indicating the effect of nuclear NF-AT3 and NF-AT4 on
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pression in the right and left atria correlated significantly
with PICP and TGF-β1 levels in the blood of patients
with AF. Nuclear NF-AT4 levels in left atria correlated
significantly with PICP and TGF-β1 levels, while those in
the right atria correlated significantly with PICP and
PINP levels in the blood of patients with AF. Therefore,
we conclude that PICP and TGF-β1 may be useful serum
fibrosis biomarkers to estimate the extent of atrial re-
modeling due to atrial fibrillation or other risk factors.
Conclusion
We demonstrate that NF-AT3 and NF-AT4 expression
were increased in patients with atrial fibrillation. Fur-
thermore, nuclear NF-AT3 and NF-AT4 expression were
correlated significantly with levels of collagen I and III l
in the atrium and with PICP and TGF-β1 levels in the
blood. These data support the hypothesis that nuclear
NF-AT3 and NF-AT4 participates in atrial structural
remodeling, and that PICP and TGF-β1 levels may be
sensitive serum biomarkers to estimate atrial structural
remodeling. However, because there are many risk fac-
tors for AF, the mechanism of NF-AT3 and NF-AT4 ex-
pression in atrial structural remodeling requires further
investigation.Abbreviations
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disease; NF-AT3: Nuclear factor of activated T cells 3; NF-AT4: Nuclear factor of
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procollagen propeptides; SR: Sinus rhythm; VHD: Valvular heart disease.
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